At the news
? BULLISHIMPACT 6/10 8-K filed Sep 9, 2026 at 07:34 ET
Pyxis Oncology announced positive updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The data show a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months, and a 12-month overall survival probability of 79%, substantially exceeding historical control benchmarks. Safety was manageable with dose capping, supporting advancement into a pivotal Phase 3 trial (Headliner) planned for mid-2027.
- 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR) in 2L+ R/M HNSCC (N=33 efficacy evaluable)
- Median progression-free survival (mPFS) of 6.2 months; 12-month overall survival probability of 79% (median OS not yet reached)
- Clinical activity observed across HPV status and prior-treatment subgroups, including prior EGFRi-exposed patients
- No new safety signals; dose capping reduced frequency and severity of adverse events, especially peripheral neuropathy
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access